UY40644A - Compuestos derivados benzimidazólicos farmacológicamente activos, con alta afinidad a los receptores MT1 y MT2 de la melatonina y baja afinidad a las enzimas del complejo CYP450, especialmente a la CYP1A2. Sus composiciones farmacéuticas aceptables y procedimiento de producción de los mismos. - Google Patents
Compuestos derivados benzimidazólicos farmacológicamente activos, con alta afinidad a los receptores MT1 y MT2 de la melatonina y baja afinidad a las enzimas del complejo CYP450, especialmente a la CYP1A2. Sus composiciones farmacéuticas aceptables y procedimiento de producción de los mismos.Info
- Publication number
- UY40644A UY40644A UY0001040644A UY40644A UY40644A UY 40644 A UY40644 A UY 40644A UY 0001040644 A UY0001040644 A UY 0001040644A UY 40644 A UY40644 A UY 40644A UY 40644 A UY40644 A UY 40644A
- Authority
- UY
- Uruguay
- Prior art keywords
- pharmaceutical compositions
- melatonin
- receptors
- cyp450
- benzimidazole derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102016024814A BR102016024814A2 (pt) | 2016-10-24 | 2016-10-24 | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| UY0001037334A UY37334A (es) | 2016-10-24 | 2017-07-19 | Compuesto, procedimiento de obtención del compuesto, composición farmacéutica, uso del compuesto y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY40644A true UY40644A (es) | 2024-02-29 |
Family
ID=62023150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001040644A UY40644A (es) | 2016-10-24 | 2017-07-19 | Compuestos derivados benzimidazólicos farmacológicamente activos, con alta afinidad a los receptores MT1 y MT2 de la melatonina y baja afinidad a las enzimas del complejo CYP450, especialmente a la CYP1A2. Sus composiciones farmacéuticas aceptables y procedimiento de producción de los mismos. |
| UY0001037334A UY37334A (es) | 2016-10-24 | 2017-07-19 | Compuesto, procedimiento de obtención del compuesto, composición farmacéutica, uso del compuesto y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037334A UY37334A (es) | 2016-10-24 | 2017-07-19 | Compuesto, procedimiento de obtención del compuesto, composición farmacéutica, uso del compuesto y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10781182B2 (enExample) |
| EP (2) | EP3529234B1 (enExample) |
| JP (1) | JP7194683B2 (enExample) |
| KR (1) | KR102594251B1 (enExample) |
| CN (2) | CN110088092B (enExample) |
| AR (1) | AR109467A1 (enExample) |
| AU (1) | AU2017351756B2 (enExample) |
| BR (1) | BR102016024814A2 (enExample) |
| CA (1) | CA3042040A1 (enExample) |
| CL (1) | CL2019001105A1 (enExample) |
| CO (1) | CO2019004756A2 (enExample) |
| DK (1) | DK3529234T3 (enExample) |
| EC (1) | ECSP19032963A (enExample) |
| ES (2) | ES3013994T3 (enExample) |
| FI (1) | FI3529234T3 (enExample) |
| MX (1) | MX392990B (enExample) |
| PE (2) | PE20191046A1 (enExample) |
| PT (1) | PT3529234T (enExample) |
| SG (2) | SG10202009001TA (enExample) |
| UY (2) | UY40644A (enExample) |
| WO (1) | WO2018076090A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| PT3433256T (pt) | 2016-10-24 | 2019-10-31 | Astrazeneca | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]isoquinolina úteis no tratamento do cancro |
| KR102246668B1 (ko) | 2017-01-30 | 2021-04-29 | 아스트라제네카 아베 | 에스트로겐 수용체 조절인자 |
| AR121842A1 (es) * | 2020-04-15 | 2022-07-13 | Ache Laboratorios Farmaceuticos Sa | Compuesto de benzimidazol para el tratamiento de trastornos metabólicos |
| PE20221838A1 (es) | 2020-04-24 | 2022-11-29 | Astrazeneca Ab | Formulaciones farmaceuticas |
| IL297216A (en) | 2020-04-24 | 2022-12-01 | Astrazeneca Ab | Dosage regimen for the treatment of cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5260051A (en) | 1990-12-17 | 1993-11-09 | Lever Brothers Company, Division Of Conopco, Inc. | Compositions comprising phosphate ester compounds containing a beneficial reagent component |
| FR2674524B1 (fr) | 1991-03-25 | 1993-05-21 | Adir | Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2680366B1 (fr) | 1991-08-13 | 1995-01-20 | Adir | Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9326192D0 (en) | 1993-12-22 | 1994-02-23 | Glaxo Group Ltd | Chemical compounds |
| EP0788795B1 (en) * | 1994-06-10 | 2002-11-13 | Nauchno-Issledovatelsky Institut Farmakologii Akademii Meditsinskikh Nauk | Pharmacologically active 2-mercaptobenzimidazole derivatives |
| US5496826A (en) | 1994-09-02 | 1996-03-05 | Bristol-Myers Squibb Company | Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides |
| FR2738818B1 (fr) | 1995-09-18 | 1997-12-05 | Valentonine | Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament |
| US6034239A (en) * | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| JP2884153B2 (ja) * | 1996-03-08 | 1999-04-19 | 武田薬品工業株式会社 | 三環性化合物、その製造法および剤 |
| WO1998025606A1 (en) | 1996-12-10 | 1998-06-18 | Bristol-Myers Squibb Company | Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents |
| CA2334299A1 (en) | 1998-06-05 | 1999-12-09 | Pierre Dextraze | Heterocyclic cis cyclopropane derivatives as melatonergic agents |
| AU763963B2 (en) | 1999-06-30 | 2003-08-07 | Bristol-Myers Squibb Company | Heterocyclic aminopyrrolidine derivatives as melatonergic agents |
| EP1467986A1 (en) * | 2002-01-17 | 2004-10-20 | Eli Lilly And Company | Aza-cyclic compounds as modulators of acetylcholine receptors |
| WO2005080334A1 (ja) * | 2004-02-23 | 2005-09-01 | Dainippon Sumitomo Pharma Co., Ltd. | 新規へテロ環化合物 |
| ES2264641B1 (es) * | 2005-06-17 | 2008-03-01 | Quimica Sintetica, S.A. | Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios. |
| JP2010503654A (ja) * | 2006-09-12 | 2010-02-04 | ファイザー・プロダクツ・インク | ベンゾイミダゾロン誘導体 |
| WO2008051533A2 (en) * | 2006-10-25 | 2008-05-02 | Takeda Pharmaceutical Company Limited | Benzimidazole compounds |
| RU2401831C2 (ru) | 2008-12-15 | 2010-10-20 | Алла Хем, Ллс | Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения |
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
-
2016
- 2016-10-24 BR BR102016024814A patent/BR102016024814A2/pt not_active Application Discontinuation
-
2017
- 2017-07-19 UY UY0001040644A patent/UY40644A/es not_active Application Discontinuation
- 2017-07-19 UY UY0001037334A patent/UY37334A/es active IP Right Grant
- 2017-08-30 AR ARP170102402A patent/AR109467A1/es active IP Right Grant
- 2017-10-23 AU AU2017351756A patent/AU2017351756B2/en active Active
- 2017-10-23 ES ES20185268T patent/ES3013994T3/es active Active
- 2017-10-23 CA CA3042040A patent/CA3042040A1/en active Pending
- 2017-10-23 EP EP17865155.0A patent/EP3529234B1/en active Active
- 2017-10-23 WO PCT/BR2017/050320 patent/WO2018076090A1/en not_active Ceased
- 2017-10-23 CN CN201780079647.XA patent/CN110088092B/zh active Active
- 2017-10-23 SG SG10202009001TA patent/SG10202009001TA/en unknown
- 2017-10-23 US US16/344,721 patent/US10781182B2/en active Active
- 2017-10-23 FI FIEP17865155.0T patent/FI3529234T3/fi active
- 2017-10-23 EP EP20185268.8A patent/EP3741760B1/en active Active
- 2017-10-23 MX MX2019004782A patent/MX392990B/es unknown
- 2017-10-23 SG SG11201903113TA patent/SG11201903113TA/en unknown
- 2017-10-23 JP JP2019542758A patent/JP7194683B2/ja active Active
- 2017-10-23 DK DK17865155.0T patent/DK3529234T3/da active
- 2017-10-23 CN CN202210815568.3A patent/CN115181108A/zh active Pending
- 2017-10-23 PT PT178651550T patent/PT3529234T/pt unknown
- 2017-10-23 PE PE2019000861A patent/PE20191046A1/es unknown
- 2017-10-23 KR KR1020197011842A patent/KR102594251B1/ko active Active
- 2017-10-23 ES ES17865155T patent/ES2970546T3/es active Active
- 2017-10-23 PE PE2023002494A patent/PE20250558A1/es unknown
-
2019
- 2019-04-23 CL CL2019001105A patent/CL2019001105A1/es unknown
- 2019-05-09 CO CONC2019/0004756A patent/CO2019004756A2/es unknown
- 2019-05-09 EC ECSENADI201932963A patent/ECSP19032963A/es unknown
-
2020
- 2020-05-13 US US15/930,990 patent/US11091445B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY40644A (es) | Compuestos derivados benzimidazólicos farmacológicamente activos, con alta afinidad a los receptores MT1 y MT2 de la melatonina y baja afinidad a las enzimas del complejo CYP450, especialmente a la CYP1A2. Sus composiciones farmacéuticas aceptables y procedimiento de producción de los mismos. | |
| MX386187B (es) | Compuestos de benzo[b]tiofeno como agonistas de sting. | |
| CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| CO2017011017A2 (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| MX2019010541A (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
| MX380753B (es) | Lactamas bicíclicas y métodos de uso de las mismas. | |
| CL2012002057A1 (es) | Compuestos macrociclicos sustituidos, como inhibidores del virus de la hepatitis c; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, utiles como agente antivirales. | |
| MX2019001096A (es) | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. | |
| CR20170575A (es) | Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los continen. | |
| UY33943A (es) | Derivados espirocíclicos de isoxazolina como agentes antiparasitarios. | |
| CU20160063A7 (es) | Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x | |
| CL2012002771A1 (es) | Compuestos derivados de ariletinilo sustituidos, moduladores de los receptores mglur5; proceso de obtencion; composicion farmaceutica; y su uso en el tratamiento o prevencion de la esquizofrenia, enfermedades cognitivas, sindrome de x fragil o el autismo. | |
| MX373247B (es) | Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina. | |
| UY34220A (es) | Indazoles, composiciones farmacéuticas y uso de los mismos | |
| MX2015011367A (es) | Ciclodextrina y formulaciones de conjugados anticuerpo-farmaco. | |
| UY34541A (es) | ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?. | |
| MX393879B (es) | Métodos de preparación de niraparib. | |
| GT201600269A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
| SV2017005381A (es) | Compuestos de imidazopiridazina | |
| NI202000028A (es) | Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CR20110630A (es) | Compuestos carboxamida y su uso como inhibidores de calpaína | |
| MX376414B (es) | Derivados de fenilo como agonistas del receptor de canabinoides 2. | |
| UY33976A (es) | Derivados de pirazolo-pirimidina. | |
| CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RDES | Application refused |
Effective date: 20241125 |